• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients.

作者信息

Negishi Mayumi, Shimomura Kenju, Proks Peter, Shimomura Yohnosuke, Mori Masatomo

出版信息

Br J Clin Pharmacol. 2008 Aug;66(2):318-9. doi: 10.1111/j.1365-2125.2008.03216.x. Epub 2008 Apr 30.

DOI:10.1111/j.1365-2125.2008.03216.x
PMID:18507653
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2492932/
Abstract
摘要

相似文献

1
Alpha glucosidase inhibitor voglibose can prevent pioglitazone-induced body weight gain in Type 2 diabetic patients.α-葡萄糖苷酶抑制剂伏格列波糖可预防2型糖尿病患者中吡格列酮引起的体重增加。
Br J Clin Pharmacol. 2008 Aug;66(2):318-9. doi: 10.1111/j.1365-2125.2008.03216.x. Epub 2008 Apr 30.
2
Comparison of the effects of pioglitazone and voglibose on circulating total and high-molecular-weight adiponectin, and on two fibrinolysis inhibitors, in patients with Type 2 diabetes.吡格列酮与伏格列波糖对2型糖尿病患者循环中总脂联素和高分子量脂联素以及两种纤溶抑制剂影响的比较
Diabet Med. 2007 Sep;24(9):962-8. doi: 10.1111/j.1464-5491.2007.02204.x. Epub 2007 May 17.
3
Beneficial effect of long-term combined treatment with voglibose and pioglitazone on pancreatic islet function of genetically diabetic GK rats.伏格列波糖与吡格列酮长期联合治疗对遗传性糖尿病GK大鼠胰岛功能的有益作用。
Horm Metab Res. 1998 Nov;30(11):673-8. doi: 10.1055/s-2007-978956.
4
Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients.吡格列酮对2型糖尿病肾病患者颈动脉内膜中层厚度及动脉僵硬度的影响。
Metabolism. 2004 Oct;53(10):1382-6. doi: 10.1016/j.metabol.2004.05.013.
5
Residual effect of reductions in red blood cell count and haematocrit and haemoglobin levels after 10-month withdrawal of pioglitazone in patients with Type 2 diabetes.2型糖尿病患者停用吡格列酮10个月后红细胞计数、血细胞比容和血红蛋白水平降低的残留效应。
Diabet Med. 2014 Nov;31(11):1341-9. doi: 10.1111/dme.12481. Epub 2014 May 30.
6
Comparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndrome.比较吡格列酮与伏格列波糖治疗代谢综合征伴 2 型糖尿病患者的代谢特征和脂联素水平。
Endocr J. 2011;58(6):425-32. doi: 10.1507/endocrj.k10e-327. Epub 2011 Apr 17.
7
Adverse effect of pioglitazone in military personnel and their families: a preliminary report.
J Med Assoc Thai. 2009 Feb;92 Suppl 1:S124-8.
8
The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.新型降血糖药物YM440可使糖尿病db/db小鼠的高血糖恢复正常，且不改变体脂重量。
Metabolism. 2000 Mar;49(3):411-7. doi: 10.1016/s0026-0495(00)90440-2.
9
Pioglitazone induced reversible pancytopenia.吡格列酮诱发可逆性全血细胞减少。
Exp Clin Endocrinol Diabetes. 2010 Feb;118(2):96-7. doi: 10.1055/s-0029-1234065. Epub 2009 Oct 15.
10
Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.一项多中心、观察性、开放标签、药物监测研究中，使用吡格列酮治疗2年的2型糖尿病患者的耐受性结果。
Clin Ther. 2009 Jan;31(1):74-88. doi: 10.1016/j.clinthera.2009.01.004.

引用本文的文献

1
Real-World Assessment of Personalized Approach With Voglibose Fixed-Dose Combination in Type 2 Diabetes Mellitus.伏格列波糖固定剂量组合个性化方案在2型糖尿病中的真实世界评估
Cureus. 2024 Apr 3;16(4):e57494. doi: 10.7759/cureus.57494. eCollection 2024 Apr.
2
Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases.慢性肝病患者糖尿病的临床意义、诊断及管理
World J Hepatol. 2020 Sep 27;12(9):533-557. doi: 10.4254/wjh.v12.i9.533.
3
Voglibose: an alpha glucosidase inhibitor.伏格列波糖：一种α-葡萄糖苷酶抑制剂。
J Clin Diagn Res. 2013 Dec;7(12):3023-7. doi: 10.7860/JCDR/2013/6373.3838. Epub 2013 Dec 15.
4
Effect of Green Tea Extract/Poly-γ-Glutamic Acid Complex in Obese Type 2 Diabetic Mice.绿茶提取物/聚谷氨酸复合物对肥胖 2 型糖尿病小鼠的影响。
Diabetes Metab J. 2013 Jun;37(3):196-206. doi: 10.4093/dmj.2013.37.3.196. Epub 2013 Jun 14.
5
Green tea extract with polyethylene glycol-3350 reduces body weight and improves glucose tolerance in db/db and high-fat diet mice.表没食子儿茶素没食子酸酯与聚乙二醇 3350 联合使用可降低 db/db 及高脂饮食小鼠的体重并改善葡萄糖耐量。
Naunyn Schmiedebergs Arch Pharmacol. 2013 Aug;386(8):733-45. doi: 10.1007/s00210-013-0869-9. Epub 2013 Apr 27.
6
Optimizing weight control in diabetes: antidiabetic drug selection.优化糖尿病患者的体重控制：降糖药物选择。
Diabetes Metab Syndr Obes. 2010 Aug 24;3:297-9. doi: 10.2147/DMSOTT.S11941.

本文引用的文献

1
alpha-Glucosidase inhibitors prevent diet-induced increases in intestinal sugar transport in diabetic mice.α-葡萄糖苷酶抑制剂可预防糖尿病小鼠饮食诱导的肠道糖转运增加。
Metabolism. 2006 Jun;55(6):832-41. doi: 10.1016/j.metabol.2006.02.011.
2
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.吡格列酮对身体成分和能量消耗的影响：一项随机对照试验。
Metabolism. 2005 Jan;54(1):24-32. doi: 10.1016/j.metabol.2004.07.008.
3
Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.使用过氧化物酶体增殖物激活受体γ配体罗格列酮治疗48周后，非酒精性脂肪性肝炎病情改善。
Hepatology. 2003 Oct;38(4):1008-17. doi: 10.1053/jhep.2003.50420.
4
Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes.吡格列酮可降低2型糖尿病患者的肝脏脂肪含量并增加内脏葡萄糖摄取。
Diabetes. 2003 Jun;52(6):1364-70. doi: 10.2337/diabetes.52.6.1364.
5
Miglitol, a new alpha-glucosidase inhibitor.米格列醇，一种新型α-葡萄糖苷酶抑制剂。
Expert Opin Pharmacother. 1999 Nov;1(1):149-56. doi: 10.1517/14656566.1.1.149.
6
Efficacy of troglitazone on body fat distribution in type 2 diabetes.曲格列酮对2型糖尿病患者体脂分布的疗效。
Diabetes Care. 2000 Aug;23(8):1067-71. doi: 10.2337/diacare.23.8.1067.
7
Effect of troglitazone on body fat distribution in type 2 diabetic patients.曲格列酮对2型糖尿病患者体脂分布的影响。
Diabetes Care. 1999 Jun;22(6):908-12. doi: 10.2337/diacare.22.6.908.
8
Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes.
Diabetes Care. 1999 Feb;22(2):288-93. doi: 10.2337/diacare.22.2.288.
9
Effects of alpha-glucosidase inhibitor (acarbose) combined with sulfonylurea or sulfonylurea and metformin in treatment of non-insulin-dependent diabetes mellitus.α-葡萄糖苷酶抑制剂（阿卡波糖）联合磺脲类药物或磺脲类药物与二甲双胍治疗非胰岛素依赖型糖尿病的疗效
J Med Assoc Thai. 1995 Nov;78(11):578-85.
10
Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential.
Drugs. 1988 Mar;35(3):214-43. doi: 10.2165/00003495-198835030-00003.